SWI/SNF Deficiency Results in Aberrant Chromatin Organization

Total Page:16

File Type:pdf, Size:1020Kb

SWI/SNF Deficiency Results in Aberrant Chromatin Organization Molecular Biology of the Cell Vol. 20, 3192–3199, July 15, 2009 SWI/SNF Deficiency Results in Aberrant Chromatin Organization, Mitotic Failure, and Diminished Proliferative Capacity Ryan J. Bourgo,* Hasan Siddiqui,† Sejal Fox,‡ David Solomon,§ Courtney G. Sansam,ʈ Moshe Yaniv,¶ Christian Muchardt,¶ Daniel Metzger,# Pierre Chambon,# Charles W.M. Roberts,ʈ and Erik S. Knudsen* *Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107; †Human Cancer Genetics Program, Department of Molecular Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, College of Medicine and Public Health, The Ohio State University, Columbus, OH 43210; ‡Department of Cell and Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH 45267; §Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC, 20057; ¶Expression Ge´ne´tique et Maladies, Formation de Recherche en Evolution 2850 du Centre National de la Recherche Scientifique, De´partement de Biologie du De´veloppement, Institut Pasteur, 75724 Paris, France; #Institut de Ge´ne´tique et Biologie Mole´culaire et Cellulaire, Department of Functional Genomics, F-67400 Illkirch, France; Institut National de la Sante´ et de la Recherche Me´dicale, U596, F-67400 Illkirch, France; Centre National de la Recherche Scientifique, Unite´ Mixte de Recherche 7104, F-67400 Illkirch, France; Universite´ Louis Pasteur, F-67000 Strasbourg, France; Colle´ge de France, F-67400 Illkirch, France; and ʈDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115 Submitted December 19, 2008; Revised April 13, 2009; Accepted May 11, 2009 Monitoring Editor: J. Silvio Gutkind Switch (SWI)/sucrose nonfermentable (SNF) is an evolutionarily conserved complex with ATPase function, capable of regulating nucleosome position to alter transcriptional programs within the cell. It is known that the SWI/SNF complex is responsible for regulation of many genes involved in cell cycle control and proliferation, and it has recently been implicated in cancer development. The ATPase action of SWI/SNF is conferred through either the brahma-related gene 1 (Brg1) or brahma (Brm) subunit of the complex, and it is of central importance to the modification of nucleosome position. In this study, the role of the Brg1 and Brm subunits were examined as they relate to chromatin structure and organization. Deletion of the Brg1 ATPase results in dissolution of pericentromeric heterochromatin domains and a redistribution of histone modifications associated with these structures. This effect was highly specific to Brg1 and is not reproduced by the loss of Brm or SNF5/BAF47/INI1. Brg1 deficiency is associated with the appearance of micronuclei and aberrant mitoses that are a by-product of dissociated chromatin structure. Thus, Brg1 plays a critical role in maintaining chromatin structural integrity. INTRODUCTION both Brg1 and Brm can function as the central ATPase in the SWI/SNF complex, each defines a discrete complex with The switch/sucrose nonfermentable (SWI/SNF) complex unique biochemical activity. In addition, specific accessory uses the energy of ATP hydrolysis to modulate nucleosome factors interact with the ATPase subunits and play critical position and density across promoters and thus plays an roles in chromatin remodeling activity. For example, SNF5/ important role in regulating gene expression. The SWI/SNF BAF47/INI1 is present in both Brg1- and Brm-associated ATPase function is necessary for its chromatin remodeling complexes and is required for maximal chromatin remodel- activities (Laurent et al., 1993), and this function is mani- ing activity, both in vitro and in yeast. Surprisingly, al- fested through one of two mutually exclusive subunits, though Brg1 and Brm have Ͼ75% sequence homology, the brahma-related gene 1 (Brg1) or brahma (Brm). Although impact of each individual subunit on chromatin biology and underlying cell biology is poorly understood (Phelan et al., 1999). This article was published online ahead of print in MBC in Press Due to its central function in chromatin remodeling, SWI/ (http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E08–12–1224) SNF function is required in many facets of gene regulation. on May 20, 2009. Correspondingly, it is estimated that approximately 5% of Address correspondence to: Ryan J. Bourgo (ryan.bourgo@jefferson. the yeast genome is transcriptionally regulated by the SWI/ edu). SNF complex (Holstege et al., 1998; Sudarsanam et al., 2000). Abbreviations used: Brg1, brahma-related gene 1; Brm, brahma; RB, In mammalian cells, SWI/SNF plays a critical role in the retinoblastoma; SNF, sucrose nonfermentable; SNF5, SNF5/BAF47/ activation of a diverse set of genes and has been shown to be INI1; SWI, switch. recruited directly to transcriptional activation domains (De- 3192 © 2009 by The American Society for Cell Biology SWI/SNF Deficiency Causes Failed Mitosis roo and Archer, 2001; Hassan et al., 2001). In contrast, SWI/ analyzed by PCR using a combination of three different primers: sense 5Ј- Ј Ј SNF is also required for transcriptional repression. For ex- CCTGAGTCATTTGCTATAGCCTGTG-3 , antisense 5 -GGACTGCCAGCT- GCA-GAG-3Ј, and 5Ј-CATCGCCTTCTAT-CGCCTTC-3Ј. For mouse genotyp- ample, transcriptional repression of cell cycle genes ing (Brg1), mouse tail DNA was extracted and analyzed by using the mediated by the retinoblastoma tumor suppressor is depen- following primers: sense 5Ј-GATCAGCTCATGCCCTAAGG-3Ј and antisense dent on SWI/SNF, implicating the involvement of SWI/SNF 5Ј-CCTACAGTTCCATG-CAGCTGG-3Ј. in cellular proliferation (Gunawardena et al., 2004, 2007). Paradoxically, disruption of SWI/SNF function has alter- Retroviral Transduction, Plasmid Transfection, and natively been associated with tumorigenesis and lack of Selection cellular/organismal viability. Specifically, loss or mutation of the SNF5/INI1 subunit is associated with rhabdoid tu- Retroviral Transduction. Cells were transduced for 7 h with a retrovirus morigenesis, and it has been convincingly demonstrated that containing a p53 dominant-negative allele (p53DD). The transduced cells were selected for 14 d in 0.2 mg/ml G418 sulfate (Calbiochem, San Diego, CA). the SNF5/INI1 gene acts as a tumor suppressor (Biegel et al., 1999; Sevenet et al., 1999; Roberts et al., 2002). Correspond- Plasmid Transfection. Cells were transfected for 18 h using Lipofectin trans- ingly, diminished expression or loss of Brg1, Brm, Baf57, fection reagent (Invitrogen, Carlsbad, CA) following manufacturer-provided Baf180, and several other chromatin-modifying genes has protocol. After 48 h, cells were passaged into 2 ␮g/ml puromycin for 7 d. been observed in cancer cell lines and tumor specimens These cells were passaged again into 2 ␮g/ml puromycin for another 7 d (Gregory and Shiekhattar, 2004). However, these implica- before beginning experimental procedures. tions in tumor development are seemingly at odds with important roles for SWI/SNF subunits in maintaining cellu- RESULTS lar viability and proliferative capacity (Bultman et al., 2000). It is well known that chromosomal instability is a hall- Targeted Deletion of SWI/SNF ATPases in Cell Culture mark of cancer. Interestingly, loss of chromatin regulatory The SWI/SNF complex is implicated in a wide range of proteins can have deleterious effects on chromatin structure highly cancer-relevant processes, such as transcriptional reg- that can compromise genome stability and fuel tumorigen- ulation, cell cycle control, and DNA repair. Here, models of esis (David et al., 2003, 2006). Here, we used somatic cell Brg1 and Brm knockout were used to directly define the culture models to define the impact of the SWI/SNF chro- impact of deficiency of these subunits on cellular function. matin-modifying complex on chromatin biology and cell To perform these studies, we utilized mouse adult fibro- Ϫ Ϫ cycle progression. blasts that were derived from Brg1f/f, Brm / , and com- pound BrmϪ/ϪBrg1f/f mice. By employing Cre-recombinase in vitro, any combination of core ATPase deficiency could be MATERIALS AND METHODS created (Supplemental Figure S1A). Cell cultures were trans- Cell Culture and Adenoviral Transduction duced with adenoviruses encoding either GFP or GFP-Cre, Ͼ Primary and 3T3 cell lines were cultured in DMEM supplemented with 10% and analyses of GFP-fluorescence revealed 95% of cells heat-inactivated fetal bovine serum, 100 U/ml penicillin-streptomycin, and 2 were infected. Correspondingly, the Brg1lox allele was effi- mM l-glutamine at 37°C in 5% CO2. All cell lines were transduced with ciently recombined in those cultures subjected to infection adenoviruses encoding green fluorescent protein (GFP), GFP-Cre recombi- with GFP-Cre encoding adenoviruses (Supplemental Figure nase (Cre), or Cre for 120 h. S1B). Consistent with the genetic recombination, the expres- Immunoblotting sion of Brg1 protein was significantly reduced at 120 h after Cell lysates were resolved by SDS-polyacrylamide gel electrophoresis (PAGE) infection (Figure 1A). As expected, the Brm knockout cell and transferred to Immobilon-P membrane (Millipore, Billerica, MA). Mem- cultures exhibited the appropriate genomic organization of branes were incubated with the following primary antibodies: Brg1 (sc-17796; the targeted allele and failed to express Brm protein (Figure Santa Cruz Biotechnology, Santa Cruz, CA), Brm (sc-17828; Santa Cruz Biotech- 1A). Thus, each combination of ATPase deficiency could be nology), vimentin (gift from Dr. Wallace
Recommended publications
  • Redundancy and Specificity F Mechta-Grigoriou Et Al 2379
    Oncogene (2001) 20, 2378 ± 2389 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc The mammalian Jun proteins: redundancy and speci®city Fatima Mechta-Grigoriou1, Damien Gerald1 and Moshe Yaniv*,1 1Unite des virus oncogenes, CNRS URA 1644, Institut Pasteur, 25 rue du Docteur Roux, 75724 Paris Cedex 15, France The AP-1 transcription factor is composed of a mixture transcription factors. These proteins are characterized of homo- and hetero-dimers formed between Jun and Fos by a highly charged, basic DNA binding domain, proteins. The dierent Jun and Fos family members vary immediately adjacent to an amphipathic dimerization signi®cantly in their relative abundance and their domain, referred as the `Leucine zipper' (Kouzarides interactions with additional proteins generating a and Zi, 1988; Landschulz et al., 1988). Dimerization complex network of transcriptional regulators. Thus, is required for speci®c and high anity binding to the the functional activity of AP-1 in any given cell depends palindromic DNA sequence, TGAC/GTCA (Rauscher on the relative amount of speci®c Jun/Fos proteins which et al., 1988; Gentz et al., 1989; Hirai and Yaniv, 1989; are expressed, as well as other potential interacting Ransone et al., 1989; Schuermann et al., 1989; Turner proteins. This diversity of AP-1 components has and Tjian, 1989). The dierent AP-1 dimers exhibit complicated our understanding of AP-1 function and similar DNA binding speci®cities but dier in their resulted in a paucity of information about the precise transactivation eciencies (Chiu et al., 1989; Hirai et role of individual AP-1 members in distinct cellular al., 1990; Kerppola and Curran, 1991b; Suzuki et al., processes.
    [Show full text]
  • CSHL AR 1981.Pdf
    ANNUAL REPORT 1981 COLD SPRING HARBOR LABORATORY Cold Spring Harbor Laboratory Box 100, Cold Spring Harbor, New York 11724 1981 Annual Report Editors: Annette Kirk, Elizabeth Ritcey Photo credits: 9, 12, Elizabeth Watson; 209, Korab, Ltd.; 238, Robert Belas; 248, Ed Tronolone. All otherphotos by Herb Parsons. Front and back covers: Sammis Hall, new residence facility at the Banbury Conference Center.Photos by K orab, Ltd. COLD SPRING HARBOR LABORATORY COLD SPRING HARBOR, LONG ISLAND, NEW YORK OFFICERS OF THE CORPORATION Walter H. Page, Chairman Dr. Bayard Clarkson, Vice-Chairman Dr. Norton D. Zinder, Secretary Robert L. Cummings, Treasurer Roderick H. Cushman, Assistant Treasurer Dr. James D. Watson, Director William R. Udry, Administrative Director BOARD OF TRUSTEES Institutional Trustees Individual Trustees Albert Einstein College of Medicine John F. Carr Dr. Matthew Scharff Emilio G. Collado Robert L. Cummings Columbia University Roderick H. Cushman Dr. Charles Cantor Walter N. Frank, Jr. John P. Humes Duke Mary Lindsay Dr. Robert Webster Walter H. Page William S. Robertson Long Island Biological Association Mrs. Franz Schneider Edward Pulling Alexander C. Tomlinson Dr. James D. Watson Massachusetts Institute of Technology Dr. Boris Magasanik Honorary Trustees Memorial Sloan-Kettering Cancer Center Dr. Bayard Clarkson Dr. Harry Eagle Dr. H. Bentley Glass New York University Medical Center Dr. Alexander Hollaender Dr. Claudio Basilico The Rockefeller University Dr. Norton D. Zinder State University of New York, Stony Brook Dr. Thomas E. Shenk University of Wisconsin Dr. Masayasu Nomura Wawepex Society Bache Bleeker Yale University Dr. Charles F. Stevens Officers and trustees are as of December 31, 1981 DIRECTOR'S REPORT 1981 The daily lives of scientists are much less filled now be solvable or whether we must await the re- with clever new ideas than the public must im- ception of some new facts that as yet do not exist.
    [Show full text]
  • Journal of Molecular Biology
    JOURNAL OF MOLECULAR BIOLOGY AUTHOR INFORMATION PACK TABLE OF CONTENTS XXX . • Description p.1 • Audience p.2 • Impact Factor p.2 • Abstracting and Indexing p.2 • Editorial Board p.2 • Guide for Authors p.6 ISSN: 0022-2836 DESCRIPTION . Journal of Molecular Biology (JMB) provides high quality, comprehensive and broad coverage in all areas of molecular biology. The journal publishes original scientific research papers that provide mechanistic and functional insights and report a significant advance to the field. The journal encourages the submission of multidisciplinary studies that use complementary experimental and computational approaches to address challenging biological questions. Research areas include but are not limited to: Biomolecular interactions, signaling networks, systems biology Cell cycle, cell growth, cell differentiation Cell death, autophagy Cell signaling and regulation Chemical biology Computational biology, in combination with experimental studies DNA replication, repair, and recombination Development, regenerative biology, mechanistic and functional studies of stem cells Epigenetics, chromatin structure and function Gene expression Receptors, channels, and transporters Membrane processes Cell surface proteins and cell adhesion Methodological advances, both experimental and theoretical, including databases Microbiology, virology, and interactions with the host or environment Microbiota mechanistic and functional studies Nuclear organization Post-translational modifications, proteomics Processing and function of biologically
    [Show full text]
  • Saturday, April 14, 2007
    Saturday, April 14, 2007 8:00-10:00 AM Educational Sessions Systems Biology as an Integrative Approach to Cancer, Arul M. Chinnaiyan, Chairperson, Room 403 A-B, Los Angeles Convention How to Design and Interpret Large-Scale Sequence Analyses of Center, p. 65 Human Cancer, Victor E. Velculescu, Chairperson, Room 408 A-B, Los Angeles Convention Center, p. 57 Targeted Cancer Therapy: Mono-specific versus Multi-targeted Strategies, Axel Ullrich, Chairperson, Concourse E, Los Angeles Manipulating the Immune System in Cancer Immunotherapy, Convention Center, p. 65 James P. Allison, Chairperson, Petree C, Los Angeles Convention Saturday Event Schedule Center, p. 58 Targeted Delivery of siRNA and Small Molecule Inhibitors, Jackson B. Gibbs, Chairperson, Concourse F, Los Angeles Convention Modeling Chemoprevention in Mice: The Next Generation, Cory Center, p. 66 Abate-Shen, Chairperson, Room 515 B, Los Angeles Convention Center, p. 58 The Ras Pathway: From Cancer Biology to Translational Opportunities, Dafna Bar-Sagi, Chairperson, Room 304 A-C, Los Novel Approaches to Drug Delivery in Cancer, Mark E. Davis, Angeles Convention Center, p. 66 Chairperson, Room 304 A-C, Los Angeles Convention Center, p. 59 Oxidative Stress and Senescence, Amato J. Giaccia, Chairperson, Room 515 A, Los Angeles Convention Center, p. 59 10:15 AM-12:15 PM Methods Workshops The Polygenic Basis of Phenotypic Variation and Disease: Lessons from Humans and Model Organisms, Bruce A. J. Ponder, Advances in Imaging: From Molecules and Live-Cell Research to Chairperson, Petree D, Los Angeles Convention Center, p. 60 Animal Models and Clinical Applications, Jiri Bartek, Chairperson, Room 515 B, Los Angeles Convention Center, p.
    [Show full text]
  • ESID Newsletter 2007 1 Contents
    Contents Obituary 2 Introduction 3 ESID information 4 President’s letter 5 Secretary’s report 5 Treasurer’s report 7 News & Views 7 Journal of Experimental Medicine 7 Genetics and Mechanisms of Susceptibility to Infectious Diseases” Pasteur Institute, aris 7 21-24 November 2007 The 6th Prague Spring ESID Meeting , Prague, May 14 and 15, 2007 8 Suggestions to the ESID community for the Journal of Primary Immunodeficiency? 9 ESID Prague Spring Meeting, May 14 and 15, 2007 FORM 10 Scheduled J Project Meetings (No. 19 to 21) 2007 11 Report on the 1st J Project Meeting in Bucharest 11 J Project meeting in Zaporozhye, East-Ukraine, 19-20 April 2007 12 Laboratory of Human Genetics of Infectious Diseases, post-doc positions 12 Working Party reports 13 Educational 13 Genetics 13 Registries 14 Juniors 19 PID care in development 19 Interesting Papers 19 Interesting Cases 21 Young Researchers’ Corner 23 Roland Levinsky, 1943-2007 Roland was a pioneer and inspirational leader in the field of primary immunodeficiency. Although originally from South Africa, Roland spent his adult life in the UK, 26 years of it at the Insti- tute of Child Health (ICH) and Great Ormond Street Hospital (GOS) in London. Roland attended medical school in London (University College London) and then trained in paediatrics in Birmingham and London before moving to Great Ormond Street Hospital in London in 1973. He subsequently became Senior Lecturer and Honorary Consultant Immunologist at GOS and Hugh Greenwood Pro- fessor of Immunology in 1985, a Chair he held at the Institute of Child Health, until he left London in 2002 to be Vice-Chancellor of Plymouth University.
    [Show full text]
  • EMBC Annual Report 2005
    EMBO | EMBC annual report 2005 EUROPEAN MOLECULAR BIOLOGY ORGANIZATION | EUROPEAN MOLECULAR BIOLOGY CONFERENCE EMBO | EMBC table of contents introduction preface by Frank Gannon, EMBO 4 preface by Susan Gasser, EMBO Council 6 preface by Marja Makarow, EMBC 8 past & present timeline 12 brief history 13 EMBO | EMBC | EMBL 14 EMBO actions 2005 17 EMBC actions 2005 19 EMBO & EMBC programmes and activities fellowship programme 23 courses & workshops programme 24 world activities 25 young investigator programme 26 women in the life sciences 27 science & society programme 28 electronic information programme 29 EMBO activities The EMBO Journal 32 EMBO reports 33 Molecular Systems Biology 34 journal subject categories 35 national science reviews 36 gold medal 37 award for communication in the life sciences 38 sectoral meetings 39 plenary lectures 40 communications offi ce 41 European Life Sciences Forum (ELSF) 42 ➔ 2 table of contents appendix EMBC delegates and advisers 46 EMBC scale of contributions 53 EMBO council members 2005 54 EMBO committee members & auditors 2005 55 EMBO council members 2006 56 EMBO committee members & auditors 2006 57 EMBO members elected in 2005 58 advisory editorial boards & senior editors 2005 66 long-term fellowship awards 2005 70 long-term fellowships: statistics 84 long-term fellowships 2005: geographical distribution 86 short-term fellowship awards 2005 88 short-term fellowships: statistics 102 short-term fellowships 2005: geographical distribution 104 young investigators 2005 106 young investigators 2000 – 2004 107 young investigators: statistics 108 young investigator lectures 2005 110 courses | workshops | conferences | symposia 2005 112 plenary lectures 2005 118 participation of women in EMBO activities: statistics 120 EMBO staff 124 events in 2006 courses | workshops | conferences | conference series | symposia 2006 128 plenary lectures 2006 134 other EMBO events 2006 136 organisations and acronyms 138 ➔ 3 preface EMBO & EMBC 2005 An awkward time warp surrounds annual 1200 applications for long-term fellowships and reports.
    [Show full text]
  • When the SWI/SNF Complex Remodels . . . the Cell Cycle
    Oncogene (2001) 20, 3067 ± 3075 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc When the SWI/SNF complex remodels . the cell cycle Christian Muchardt*,1 and Moshe Yaniv1 1Unite des Virus OncogeÁnes, URA1644 du CNRS, DeÂpartement des Biotechnologies, Institut Pasteur, Paris, France Mammalian cells contain several chromatin-remodeling particle. The exact eect of this modi®cation is still complexes associated with the Brm and Brg1 helicase- unclear but it is likely that the loss of positive charges like proteins. These complexes likely represent the modify interactions between the histone tails and the functional homologs of the SWI/SNF and RSC DNA or the neighboring nucleosomes. The reaction complexes found in Saccharomyces cerevisiae. The can be reversed by histone deacetylases (HDACs) that mammalian chromatin-remodeling complexes are in- have a negative eect on transcriptional activity. The volved in both activation and repression of a variety of second category of factors that aect chromatin genes. Several lines of evidence also indicate that they encompasses protein complexes that use the energy of play a speci®c role in the regulation of cell growth. Brm ATP-hydrolysis to weaken the interaction between is down-regulated by ras signaling and its forced re- histone core particles and DNA. These complexes expression suppresses transformation by this oncogene. facilitate the binding of transcription factors to speci®c Besides, the Brg1 gene is silenced or mutated in several DNA sites and may thus mediate both activation and tumors cell lines and a Brg1-associated complex was repression, depending on the activity of the recruited recently found to co-purify with BRCA1, involved in transcriptional regulator.
    [Show full text]
  • La Biologie De La Chromatine
    SYMPOSIUM FRANCO-ISRAELIEN SUR LA BIOLOGIE DE LA CHROMATINE FRENCH-ISRAELI INTER-ACADEMIY SYMPOSIUM ON CHROMATIN BIOLOGY 7-8 juillet 2015 July 7-8, 2015 ACADEMIE DES SCIENCES DE FRANCE FRENCH ACADEMY OF SCIENCES ACADEMIE ISRAELIENNE DES SCIENCES ET HUMANITES ISRAEL ACADEMY OF SCIENCES AND HUMANITIES COMITÉ D’ORGANISATION ORGANIZING COMMITTEE Geneviève ALMOUZNI Curie Institute, Paris Jean-François BACH French Academy of Sciences Moshe OREN the Weizmann Institute of Science, Rehovot Yosef SHILOH Tel Aviv University Moshe YANIV Pasteur Institute, Paris PARIS Académie des sciences - Grande salle des Séances 23 quai de Conti - 75006 Paris Inscription obligatoire, avant le 1er juillet 2015 [email protected] Registration required, before July 1st, 2015 [email protected] MARDI 7 JUILLET MATIN TUESDAY JULY 7, MORNING 8h30 Welcome 9h Welcome addresses Jean-François BACH, Secrétaire perpétuel of the French Academy of Sciences Ruth ARNON, President of the Israel Academy of Sciences and Humanities Yosef SHILOH, Israeli Co-President of the meeting Moshe OREN, Israeli Co-President of the meeting Geneviève ALMOUZNI, French Co-President of the meeting Moshe YANIV, French Co-President of the meeting SESSION I: CHROMATIN IN DEVELOPMENT AND STEM CELLS. CHAIR: MARGARET BUCKINGHAM, PASTEUR INSTITUTE, PARIS 9h30 Howard Cedar, the Hebrew University Medical School, Jerusalem DNA Methylation in Pre and Post Natal Development 10h Edith Heard, Curie Institute, Paris Chromosome and Chromatin Dynamics during X-Chromosome Inactivation 10h30: coffee break 11h Yehudit Bergman, the Hebrew University Medical School, Jerusalem Epigenetic Programming of Cell Fate Decisions 11h30 Saadi Khochbin, Albert Bonniot Institute, Grenoble Molecular Basis of Haploid Male Genome Programming 12h Eran Meshorer, the Hebrew University, Jerusalem Novel Chromatin Regulators of Pluripotent Stem Cells 12h30 pause déjeuner 2 MARDI 7 JUILLET, APRES-MIDI TUESDAY JULY 7, AFTERNOON SESSION II : EPIGENETICS AND TRANSCRIPTION.
    [Show full text]
  • A History of the Molecular Biology Department Benoît Robert
    A history of the Molecular Biology Department Benoît Robert To cite this version: Benoît Robert. A history of the Molecular Biology Department. 2014. pasteur-01719506 HAL Id: pasteur-01719506 https://hal-pasteur.archives-ouvertes.fr/pasteur-01719506 Preprint submitted on 28 Feb 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution - NonCommercial| 4.0 International License Benoît ROBERT: A history of the Molecular Biology Department 1961 – 1968: Genesis Coincidence of dates may be misleading to the historian. The first reunion of the Molecular Biology Department Council was held on December 12, 1968. With a date so close to the turmoil of May 19681, one could imagine that the Department was a revolutionary structure obtained after tough fights by a very demanding young generation. However, the Department has its roots much beyond 1968, and stems from two initiatives. 1) As soon as 1961, the very year of the Operon editio princeps, Jacques Monod wrote a report for the "Molecular biology" committee of the Delegation for Scientific & Technological Research (DGRST)2 emphasizing the necessity to endow molecular biology with an Institute in France entirely devoted to this new biology he had been pioneering and pleading for its construction at the Institut Pasteur.
    [Show full text]
  • Regulation of 92 Kda Type IV Collagenase Expression by the Jun Aminoterminal Kinase- and the Extracellular Signal-Regulated Kinase- Dependent Signaling Cascades
    Oncogene (1997) 14, 1481 ± 1493 1997 Stockton Press All rights reserved 0950 ± 9232/97 $12.00 Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase- dependent signaling cascades R Gum1, H Wang1, E Lengyel2, J Juarez1 and D Boyd1 1Department of Head & Neck Surgery/Tumor Biology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA; 2Department of Obstetrics and Gynecology, Technical University, Munich, Germany The 92 kDa type IV collagenase (MMP-9), which activity of a promoter driven by either the MMP-9 degrades type IV collagen, has been implicated in tissue promoter or three tandem AP-1 repeats. Conversely, remodeling. The purpose of the current study was to treatment of UM-SCC-1 cells with PMA, which determine the role of Jun amino-terminal kinase (JNK)- activates c-Raf-1, increased 92 kDa gelatinolysis. These and extracellular signal-regulated kinase- (ERK)-depen- data suggest that MMP-9 expression in UM-SCC-1 dent signaling cascades in the regulation of MMP-9 cells, is regulated by JNK- and ERK-dependent signaling expression. Towards this end, we ®rst determined the pathways. transcriptional requirements for MMP-9 promoter activity in a cell line (UM-SCC-1) which is an avid Keywords: MMP-9; type IV collagenase; JNK; ERK; secretor of this collagenase. Transfection of these cells AP-1 with a CAT reporter driven by progressive 5' deleted fragments of the MMP-9 promoter indicated the requirement of a region spanning 7144 to 773 for Introduction optimal promoter activity. DNase I footprinting revealed a protected region of the promoter spanning nucleotides The 92 kDa type IV collagenase (gelatinase B also 791 to 768 and containing a consensus AP-1 motif at known as MMP-9) plays a major role in cell 779.
    [Show full text]
  • Role of Brg1 and HDAC2 in GR Trans-Repression of the Pituitary POMC Gene and Misexpression in Cushing Disease
    Downloaded from genesdev.cshlp.org on September 27, 2021 - Published by Cold Spring Harbor Laboratory Press Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease Steve Bilodeau,1 Sophie Vallette-Kasic,1 Yves Gauthier,1 Dominique Figarella-Branger,2 Thierry Brue,2 France Berthelet,3 André Lacroix,3 Dalia Batista,4 Constantine Stratakis,4 Jeanette Hanson,5 Björn Meij,5 and Jacques Drouin1,6 1Laboratoire de génétique moléculaire, Institut de recherches cliniques de Montréal (IRCM), Montréal, Québec H2W 1R7, Canada; 2Laboratoire Interactions cellulaires neuroendocriniennes (ICNE), Université de la Méditerranée, Centre national de la recherche scientifique (CNRS) UMR 6544, Institut Jean-Roche, 13385 Marseille, France; 3Department of Medicine, Research Center, Hotel-Dieu du Centre hospitalier de l’Université de Montréal (CHUM), Montréal, Québec H2W 1T8, Canada; 4Section on Endocrinology and Genetics (SEGEN), Developmental Endocrinology Branch (DEB), National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland 20892, USA; 5Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht University, NL-3508-TD Utrecht, Netherlands Negative feedback regulation of the proopiomelanocortin (POMC) gene by the glucocorticoid (Gc) receptor (GR) is a critical feature of the hypothalamo–pituitary–adrenal axis, and it is in part exerted by trans-repression between GR and the orphan nuclear receptors related to NGFI-B. We now show that Brg1, the ATPase subunit of the Swi/Snf complex, is essential for this trans-repression and that Brg1 is required in vivo to stabilize interactions between GR and NGFI-B as well as between GR and HDAC2.
    [Show full text]
  • FLI Krebsforschung Am FLI Enneu.Indd
    In 2015, Prof. K. Lenhard Rudolph was awarded the Deutscher Krebs- preis in the category of “Experimental Research“, granted by the Leibniz-Institute on Aging - German Cancer Society and the German Cancer Foundation. Fritz Lipmann Institute (FLI) Beutenbergstraße 11 D-07745 Jena, Germany His work has significantly aected Tel +49(0)3641-65-6000 today‘s understanding of telome- Fax +49(0)3641-65-6351 [email protected] res and their role in the emergence www.leibniz-fli.de of cancer. Cancer in Old Age Prof. Matthias Doppelstein in his laudation during the ceremony for the award of the Deutscher Krebspreis to Prof. K. Lenhard Rudolph. Cancer Research at FLI 1: New Laboratory Building, Reception 2-3: Laboratory Buildings 4: Administrative Building 5-8: Laboratory Buildings Scientific Director 9: Administrative Building „Villa“ Prof. K. Lenhard Rudolph Administrative Director Dr. Daniele Barthel Board of Trustees Head: Burkhard Zinner Scientific Advisory Board Head: Prof. Moshe Yaniv (c) DominoPlus Cancer is an Age-Associated Disease Cancer Research at Leibniz Institute on Aging (FLI) - At a Glance Causes for the age-associated emergence of cancer are manifold Telomere Shortening and complex. And research is still far away from understanding the Rudolph Research Group CD44 and Metastasis of Cancer Cells During life, stem cell telomeres shorten with every cell underlying processes in detail. Herrlich Emeritus Research Group division. If these „protective caps“ are gone, cell division may Tumor stem cells and tumor cells which are capable to build result in an imbalance in the division of the chromosomes in metastases are characterized by a certain form of the surface daughter cells, leading to a chromosomal instability and protein CD44.
    [Show full text]